H. Lundbeck Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos y los beneficios de H. Lundbeck disminuyan a un ritmo anual de 3.3% y 4.9% respectivamente. Se espera que el BPA disminuya en un 3.9% al año. Se prevé que la rentabilidad financiera sea de 13% en 3 años.
Información clave
-4.9%
Tasa de crecimiento de los beneficios
-3.94%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 10.6% |
| Tasa de crecimiento de los ingresos | -3.3% |
| Rentabilidad financiera futura | 13.01% |
| Cobertura de analistas | Good |
| Última actualización | 13 Jul 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...Artículo de análisis • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...Artículo de análisis • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...Recent updates
Actualización de narrativa • Jun 22
HLUN B: Neuroscience Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their fair value estimate for H. Lundbeck at DKK 47.21.Artículo de análisis • Jun 18
H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data
H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
Actualización de narrativa • Jun 06
HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple
Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.Artículo de análisis • May 24
H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively
H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Actualización de narrativa • May 23
HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside
Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.Artículo de análisis • May 15
Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Actualización de narrativa • May 05
HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins
Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.Actualización de narrativa • Apr 20
HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook
Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.Actualización de narrativa • Apr 05
HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins
Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.Actualización de narrativa • Mar 22
HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion
Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.Actualización de narrativa • Mar 08
HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential
Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.Actualización de narrativa • Feb 22
HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook
Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.Actualización de narrativa • Feb 08
HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares
Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.Artículo de análisis • Feb 07
H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...Actualización de narrativa • Jan 25
HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook
Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.Artículo de análisis • Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Actualización de narrativa • Jan 11
HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook
Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.Actualización de narrativa • Dec 27
HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements
Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.Actualización de narrativa • Dec 13
HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares
Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.Artículo de análisis • Nov 22
The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business
H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...Artículo de análisis • Nov 15
Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates
H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...Actualización de narrativa • Sep 05
CNS Pipeline And Global Expansion Will Unlock Future Opportunities
With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.Artículo de análisis • Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
Nueva narrativa • Dec 04
Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth
Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 25,058 | 4,270 | 5,476 | 6,034 | 10 |
| 12/31/2027 | 25,866 | 4,597 | 6,175 | 6,824 | 11 |
| 12/31/2026 | 25,790 | 4,553 | 5,663 | 6,289 | 11 |
| 3/31/2026 | 25,520 | 3,730 | 4,825 | 5,448 | N/A |
| 12/31/2025 | 24,630 | 3,192 | 4,863 | 5,481 | N/A |
| 9/30/2025 | 24,078 | 3,777 | 2,778 | 3,406 | N/A |
| 6/30/2025 | 23,521 | 3,453 | 2,851 | 3,409 | N/A |
| 3/31/2025 | 22,951 | 3,257 | 2,415 | 2,997 | N/A |
| 12/31/2024 | 22,004 | 3,143 | 2,761 | 3,326 | N/A |
| 9/30/2024 | 21,441 | 2,687 | 4,936 | 5,421 | N/A |
| 6/30/2024 | 20,671 | 2,586 | 4,128 | 4,609 | N/A |
| 3/31/2024 | 20,156 | 2,416 | 4,145 | 4,663 | N/A |
| 12/31/2023 | 19,912 | 2,290 | 3,579 | 4,080 | N/A |
| 9/30/2023 | 19,614 | 2,467 | 3,528 | 4,426 | N/A |
| 6/30/2023 | 19,381 | 2,479 | 3,523 | 4,457 | N/A |
| 3/31/2023 | 18,918 | 2,384 | 3,292 | 4,102 | N/A |
| 12/31/2022 | 18,246 | 1,916 | 2,699 | 3,519 | N/A |
| 9/30/2022 | 17,619 | 1,603 | 2,051 | 2,615 | N/A |
| 6/30/2022 | 16,913 | 1,236 | 1,744 | 2,313 | N/A |
| 3/31/2022 | 16,398 | 1,109 | 1,344 | 1,959 | N/A |
| 12/31/2021 | 16,299 | 1,318 | 1,660 | 2,272 | N/A |
| 9/30/2021 | 16,521 | 1,873 | 2,405 | 2,949 | N/A |
| 6/30/2021 | 16,971 | 1,965 | 2,379 | 2,912 | N/A |
| 3/31/2021 | 17,381 | 2,110 | 3,263 | 3,757 | N/A |
| 12/31/2020 | 17,672 | 1,581 | 3,359 | 3,837 | N/A |
| 9/30/2020 | 17,818 | 904 | 2,713 | 3,171 | N/A |
| 6/30/2020 | 17,490 | 1,242 | 2,910 | 3,354 | N/A |
| 3/31/2020 | 17,366 | 1,507 | 1,502 | 1,960 | N/A |
| 12/31/2019 | 17,036 | 2,313 | N/A | 2,609 | N/A |
| 9/30/2019 | 16,811 | 3,091 | N/A | 3,621 | N/A |
| 6/30/2019 | 17,309 | 3,395 | N/A | 3,462 | N/A |
| 3/31/2019 | 17,766 | 3,606 | N/A | 4,815 | N/A |
| 12/31/2018 | 18,117 | 3,907 | N/A | 5,981 | N/A |
| 9/30/2018 | 18,313 | 3,806 | N/A | 5,922 | N/A |
| 6/30/2018 | 18,028 | 3,627 | N/A | 6,197 | N/A |
| 3/31/2018 | 17,608 | 3,236 | N/A | 5,397 | N/A |
| 12/31/2017 | 17,234 | 2,624 | N/A | 4,045 | N/A |
| 9/30/2017 | 17,007 | 2,544 | N/A | 3,731 | N/A |
| 6/30/2017 | 16,607 | 1,988 | N/A | 3,551 | N/A |
| 3/31/2017 | 16,075 | 1,612 | N/A | 3,420 | N/A |
| 12/31/2016 | 15,634 | 1,211 | N/A | 3,126 | N/A |
| 9/30/2016 | 15,202 | 290 | N/A | 4,158 | N/A |
| 6/30/2016 | 14,923 | -1,289 | N/A | 2,755 | N/A |
| 3/31/2016 | 14,801 | -5,427 | N/A | 936 | N/A |
| 12/31/2015 | 14,594 | -5,694 | N/A | 197 | N/A |
| 9/30/2015 | 14,108 | -5,879 | N/A | -1,330 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de HLUN B disminuyan en los próximos 3 años (-4.9% al año).
Beneficios vs. Mercado: Se prevé que los beneficios de HLUN B disminuyan en los próximos 3 años (-4.9% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de HLUN B disminuyan en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de HLUN B disminuyan en los próximos 3 años (-3.3% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de HLUN B disminuyan en los próximos 3 años (-3.3% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de HLUN B sea baja dentro de 3 años (13%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/14 12:07 |
| Precio de las acciones al final del día | 2026/07/14 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
H. Lundbeck A/S está cubierta por 34 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rosie Turner | Barclays |
| Charles Pitman | Barclays |
| Emily Field | Barclays |